The Cancer Breakthroughs 2020 Program is one of the most comprehensive cancer collaborative initiatives launched to date, seeking to accelerate the potential of combination immunotherapy as the next generation standard of care in cancer patients. This initiative aims to explore a new paradigm in cancer care by initiating randomized Phase II trials in patients at all stages of disease in 20 tumor types in 20,000 patients within the next 36 months. These findings will inform Phase III trials and the aspirational breakthroughs to develop an effective vaccine-based immunotherapy to combat cancer by 2020. 

What is Our Goal?

Ultimately, the aim of the “Cancer Breakthroughs 2020” is to win the war on cancer -- to get to a point in the very near future when we are managing cancer the same way we might manage any chronic disease, such as diabetes or asthma. When we can finally stop the toxic therapies, such as chemotherapy and radiation that decimate the immune system, and instead, rally the full power of the immune system and the body’s natural killer cells to fight off the cancer the way they were designed to do, the patient is not only surviving the diagnosis, but living – even thriving – with cancer.

What Makes Our Approach Unique?

The level of collaboration across pharma, community and academic oncology, government, and scientific communities within Cancer Breakthroughs 2020 is absolutely unprecedented. This joint approach provides researchers with necessary testing materials and patients with more opportunities to participate through local facilities and wider insurance coverage. Oncologists receive real time trial results, and patients have hope for more positive outcomes.